Research on the biology of tumor cells. Covers tumor spread, cell-particle diagnostics, new anti-tumor molecules, and cancer-killing immune cells.
A recent study found that a small percentage of cells in aggressive tumors can enable metastasis by recruiting surrounding cells. This discovery could lead to new approaches in preventing malignant progression of breast cancer, particularly in triple-negative types.
Researchers found that PrimPol helps cells survive chemotherapy damage by facilitating DNA repair; repressing this protein could make tumor cells more sensitive to cancer treatments. This discovery has implications for Fanconi anaemia, a rare disease with few therapeutic options.
Scientists at Rockefeller University have identified a new class of therapeutics that destroy fibrolamellar tumor cells growing in mice. The team tested over 5,000 compounds to find these effective treatments, which could potentially transform the landscape of precision medicine by tailoring treatment options for individual patients
Researchers at Université catholique de Louvain discovered that DHA slows the development of tumors by poisoning cancer cells through a phenomenon called ferroptosis. This mechanism is triggered when acidotic tumor cells absorb excessive amounts of unsaturated fatty acids, leading to cell death.
A study evaluating 22 patients with recurrent Anti-hormonal granulosa cell tumors found low-to-moderate FDG uptake and variable ERα/ERβ expression. FES-PET/CT showed promising results in identifying treatment-eligible patients, with stable tumor locations decreasing in size during anti-hormonal treatment.
Researchers have identified specific cell types and tumor pathways that can predict which kidney cancers respond to immunotherapy, offering new insights into treatment strategies. The study's findings could lead to the development of biomarkers to guide kidney cancer treatment.
Researchers discovered that metabolites from fungi and bacteria biofilms can modulate gene expression associated with tumor growth and survival. The study found that these microorganisms can endanger homeostasis in normal and neoplastic oral epithelial cells, impairing cell viability and survival.
A new single-cell analysis tool identifies a unique sub-population of macrophages in kidney tumors associated with disease recurrence. The tool, called meta-VIPER, builds on previous techniques to accurately detect gene activity in individual cells, revealing potential targets for treatment and improving clinical outcomes.
Researchers at NYU Abu Dhabi have developed a non-contact probe that enables the analysis of single cells within tumors without disrupting their spatial configurations. The tool can also introduce foreign materials to selected cells, facilitating advanced studies on complex diseases like cancer and Alzheimer's.
A multidisciplinary study has found that cells at the centre of kidney tumours have a higher potential to spread to secondary sites around the body. By contrast, cells at the tumour edge had lower rates of metastasis and growth.
Researchers find a way to target both pancreatic cancer cells and the scar tissue surrounding them, reducing tumor growth and spreading. A new clinical trial aims to test this approach with an existing anti-arthritis drug, potentially improving treatment response and patient survival.
Biomedical engineer Chase Cornelison is exploring ways to harness cancer cells to treat spinal cord injuries and restore function following brain damage. His research aims to retrain neural cells to suppress inflammation and promote repair, potentially reversing the damage caused by paralysis and diseases.
Researchers discovered that deleting the aryl hydrocarbon receptor from oral cancer cells results in a robust tumor-specific immune response, allowing mice to reject the cancer. This finding provides a new target for cancer immunotherapy treatment, potentially leading to more effective treatments.
Scientists from UNIGE and UZH used a statistical physics approach to study wound healing, identifying the scales of dominant cell interactions that govern tissue growth. The results allow for better analysis of cell front behavior in both healthy tissue and tumour development.
A new strategy combines AIEgen-mediated photodynamic therapy with Poly(I:C)-based immunotherapy to enhance anti-tumor immune responses. The system induces tumor cell death and stimulates cytokine release, demonstrating potential for preventing tumor recurrence and metastasis.
Researchers at UCSF have engineered smart immune cells effective against solid tumors, overcoming hurdles for immunotherapies. The new approach may be ready for clinical trials in the near future, offering hope for patients with previously untouchable cancers.
A new method called XYZeq allows researchers to map variation across cells in a tissue or tumor, gaining insight into their spatial location and function. The technique enables the analysis of cellular patterns in complex environments like cancerous tumors and other organs.
A recent study by Vanderbilt researchers reveals that non-cancer cells in a tumor, primarily immune cells called macrophages, have the highest glucose uptake, upending traditional models of cancer metabolism. This finding could lead to new therapies and imaging strategies.
Researchers discovered two subsets of tumor cells that can be targeted using different methods, one inducing ferroptosis and the other inhibiting antioxidant production. The study found that combining these approaches could improve treatment outcomes for small cell lung cancer patients.
Researchers discovered a cell-to-cell communication network that instructs tumor cells in tissues to regrow after genotoxic therapy. The study found that elevated p53 levels and release of interleukin-6 signal cells to activate growth signals, leading to tumor regrowth.
Researchers found that autophagy selectively degrades PKA inhibitory subunit RIa, promoting mitochondrial metabolism and tumor cell growth. Suppression of AKAP11 levels in tumor cells prevents degradation and blocks PKA activation, inhibiting tumor cell growth.
Researchers have identified a key protein, DAPK3, that plays a crucial role in the body's early immune response to cancer. The discovery highlights a new approach to cancer immunotherapy, where targeting the tumor's own innate immune system can help slow tumor growth and improve treatment outcomes.
Scientists have identified new biomarkers in exosomes produced by cancer stem cells, which could help diagnose and predict malignant melanoma. These biomarkers were found to be present in the blood of patients with different stages of the disease, distinguishing them from healthy individuals.
Researchers developed a new vaccine that uses a patient's own tumor cells to train the immune system to find and kill cancer, promoting a broad and robust immune response. The therapy has shown long-term efficacy against metastasis and relapse in mouse models, offering potential for treatment of various cancers.
Researchers at the University of Chicago developed a new therapeutic vaccine that uses a patient's own tumor cells to train their immune system to find and kill cancer. The vaccine stopped melanoma tumor growth in mouse models and promoted a broad, robust immune response, preventing new tumor growth when tumor cells were re-introduced.
Researchers have identified YAP as a key regulator in the development and spread of basal-like breast cancer. Inhibiting YAP activity with medication can significantly reduce tumour volume, offering new hope for patients' survival.
Researchers at Imperial College London have developed a new type of nanoprobe that uses second harmonic generation (SHG) to detect tumors more brightly and precisely than existing fluorescent nanoprobes. The biodegradable bioharmonophores attach specifically to tumor cells, reducing misrepresentation and improving detection sensitivity.
Researchers discovered that metastatic cancer cells use adhesion and contractility to move away from stiffer tissue, defying the typical durotaxis process. By modulating cell contractility, they can change their ability to migrate in response to environmental stiffness.
Researchers have developed a lower-dose radiopharmaceutical that improves treatment efficacy for neuroendocrine cancers while reducing side effects. The new medication uses reversible binding technology to extend its half-life in the blood, providing an extended therapeutic time window and improved treatment outcomes.
Researchers assessed tumor cell isolation and in vitro proliferation assays to predict chemotherapy response in ovarian cancer. In 12 of 14 cases, in vitro drug sensitivity correlated with clinical outcome.
Researchers successfully developed bispecific antibodies that can target and deplete cancer cells without damaging healthy ones, including mutant tumor suppressor genes like p53. These antibodies could be used 'off-the-shelf' and are a promising alternative to engineered immune cell therapies.
Researchers found that tumor cells increase SLC6A14 expression levels in response to methionine deprivation, leading to increased AMPK activation. Targeting both SLC6A14 and AMPK may drive unbalanced metabolism in starved tumor cells, promoting apoptosis.
Researchers at SCCL have found that CD4 T lymphocytes, which typically support immune responses, can also kill cancer cells directly. Up to a third of these cells were able to destroy tumor cells within five hours.
Researchers at Max Delbréck Center for Molecular Medicine in the Helmholtz Association have made significant findings on the role of chromatin modulators in tumor cell identity changes. By using a combination of CRISPR and molecular reporter technology, they found that chromatin proteins significantly influence how tumor cells change t...
Scientists visualized anti-CD20 antibody effects in tumors using innovative imaging, finding macrophages play a crucial role in therapy efficacy. The study suggests increasing macrophage presence could boost therapeutic antibody effectiveness.
Researchers use zebrafish to study human cancer and discover that the innate immune system actively destroys cancer cells. However, tumor cells can adapt and evade immune detection through a process called 'Immunoediting', leading to immunotherapy resistance.
Researchers develop a new protein, 161519 TriKE, to target cold tumors and enhance the immune response. The study found that 161519 TriKE successfully reduced tumor growth and increased overall survival in tumor-bearing mice.
Researchers discovered that human tumours contain solid and fluid cell clusters, enabling cancer cells to move and multiply. The study's findings could lead to improved cancer diagnosis and therapy, with potential applications in detecting metastatic cancer cells.
Researchers studied cell interactions in a microscopic 'cell collider' and found that normal cells repel each other's protrusions, while cancer cells try to squeeze past each other. The study suggests new approaches for understanding cancer cell behavior and identifying molecular bases for these differences.
Scientists have identified CD161 as a potential new target for immunotherapy of malignant brain tumors, including glioblastoma. The molecule suppresses the cancer-fighting activity of immune T cells, but blocking its pathway enhances the killing of tumor cells and improves survival rates in animal models.
This review article highlights the complex crosstalk between cancer stem cells (CSCs) and tumor-associated macrophages (TAMs), two key players in cancer progression. CSCs have been identified as the drivers of cancer initiation and progression, while TAMs create a protective microenvironment for CSC development and dissemination.
Researchers found that non-metastatic cells can spread to distant organs through a new mechanism involving the fibrotic niche induced by malignant cells. This discovery suggests targeting the fibrotic niche as a promising strategy to control solid tumor progression.
Researchers discovered that immunomodulatory drugs like lenalidomide and pomalidomide starve cancer cells by destabilizing essential surface proteins, ultimately inhibiting tumor growth. This finding opens up new possibilities for targeted therapies in multiple myeloma.
Researchers at Technion-Israel Institute of Technology have discovered a new pathway that targets cancer cells specifically, minimizing damage to healthy cells. The folate cycle is essential for DNA and RNA production, and the team found that tumor cells relying on the cytosolic pathway are more susceptible to targeted treatments.
Researchers have identified a little-known glycoprotein called stanniocalcin-1 that blocks the immune system's ability to fight cancer cells. By targeting this pathway, scientists hope to improve response rates to cancer immunotherapy treatments.
Researchers at MIT have devised a way to label and sequence individual RNA molecules within a tissue sample, allowing for a unique snapshot of which genes are being expressed in different parts of a cell. This technique offers new insights into how gene expression is influenced by a cell's location or its interactions with nearby cells.
Researchers at Tokyo University of Science explore the structure of porphyrin derivatives to selectively target cancer cells and improve drug delivery. They found that meso-derivatives accumulate in cells at 3-fold higher amounts than β-derivatives, and that smaller functional groups allow better aggregation.
Researchers at Boston University School of Medicine have identified genetic dependencies in tumors that have undergone whole genome doubling. The study found that WGD tumor cells possess unique vulnerabilities that can be targeted by new therapeutics.
Researchers developed a BCL strategy to generate highly potent tumor-targeted drugs from non-toxic compounds within the tumor, avoiding decomposition and side effects. The targeting drug Ru-rhein exhibits high anti-cancer activity against lung cancer cells while being non-toxic to normal cells.
Researchers at UT Southwestern Medical Center have discovered that removing a key gene called Cbl-b can revitalize exhausted CD8+ T cells to combat malignant tumors. This breakthrough could offer a new approach to harnessing the body's immune system to fight cancers.
Researchers at Moffitt Cancer Center discovered that cancer cells can fuse and recombine their genetic material, leading to increased diversity and adaptability. This mechanism, similar to parasexual recombination in pathogenic microbes, enables cancer cells to rapidly evolve and acquire resistance to treatments.
Cancer cells can thrive in hostile environments through metabolic adaptation known as the Warburg Effect. Moffitt researchers found that activation of transcription factor KLF4 allows cells to select for this phenotype, enabling them to survive and thrive in poor conditions.
Researchers developed CopyKAT, a new computational technique that accurately differentiates between cancer and normal cells in solid tumor samples. The tool uses gene expression data to identify aneuploidy and distinct subpopulations within cancer cells.
Researchers from UC3M and UCM developed a mathematical model to understand how cancer cells invade healthy tissue, using topological data analysis techniques. The model simulates the collective movement of cells in tissues and can be used to track the progression of tumor growth.
A new study published in Cell reveals that RNA splicing therapeutics can activate antiviral immune pathways in triple negative breast cancers, triggering tumor cell death and signaling the body's immune response. The discovery highlights a novel mechanism for turning on the immune system in aggressive cancers.
Researchers developed a gene expression signature that robustly predicts patient survival in patients with peritoneal carcinomatosis, a form of metastatic gastric cancer. The signature is associated with tumor cell populations and lineage compositions, offering potential for tailored treatment strategies.
Researchers have developed molecular reporters that reveal how immune cells strengthen brain tumors, making them more aggressive. The technology has the potential to guide therapy development and is applicable to various biological systems.
Researchers have developed nanoparticles that can breach cell barriers and kill tumor cells, reducing tumor sizes by 40-70% in mice. The highly selective toxicity of the particles offers new hope for treating aggressive cancers.
Researchers found that targeting the fas protein can prevent cancer cells from escaping immunotherapies, leading to longer-lasting positive responses and improved survival rates. By combining immunotherapies with small molecule inhibitors, bystander tumor cell killing may be potentiated to eliminate antigen-loss variants.
Researchers developed inhibitors targeting mitochondrial DNA, affecting only rapidly dividing cells like cancer cells. Treatment stopped cell proliferation and reduced tumour growth without harming healthy cells.